key: cord-0835794-uw25m7rr
authors: Yuan, Shu; Jiang, Si‐Cong; Zhang, Zhong‐Wei; Fu, Yu‐Fan; Li, Zi‐Lin; Hu, Jing
title: Arrhythmia may contribute to neuropsychiatric symptoms in COVID‐19 patients
date: 2022-01-15
journal: J Med Virol
DOI: 10.1002/jmv.27583
sha: 34348c318c4a797b003db50d59b8debbf18121dc
doc_id: 835794
cord_uid: uw25m7rr

Forero-Peña et al. 1 described immediate and long-term neuropsychiatric complications following the Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, and discussed the possible roles of (hydroxy)chloroquine and dexamethasone on these neuropsychiatric symptoms… However, arrhythmia may also contribute to neuropsychiatric symptoms in COVID-19 Patients and should not be neglected. Through literature search, we summarized abnormal electrocardiographic (ECG) findings in COVID-19 patients. Sinus tachycardia was the most common arrhythmia found in the patients, with frequencies of 16.9% - 70.4% (Table 1)… Thus, anti-arrhythmic drugs, such as amiodarone and metoprolol may be used for COVID-19 patients with ventricular arrhythmia to reduce the possible complication of neuropsychiatric disorders… Chloroquine and hydroxychloroquine have been widely used in COVID-19 treatments. However, there is compelling evidence that chloroquine and hydroxychloroquine induce significant QTc prolongation and potentially increase the risk of arrhythmia… Either psychiatric symptoms or arrhythmia in COVID-19 patients undergoing steroid treatments have not been well described in the literature. This article is protected by copyright. All rights reserved.

Dear Editor, Forero-Peña et al. 1 described immediate and long-term neuropsychiatric complications following the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and discussed the possible roles of (hydroxy)chloroquine and dexamethasone on these neuropsychiatric symptoms. The patients demonstrated multiple psychiatric symptoms, including bipolar I disorder, major depressive episodes, and brief psychotic disorder. 1 This is consistent with a previous report that depression and anxiety were the most common psychological distresses across patients infected by SARS-CoV-2. 2 For (hydroxy)chloroquine administration, in four of the five patients presented, the rapid onset of symptoms after initiation of the drug and remission shortly after discontinuation, supporting (hydroxy)chloroquine as a potential trigger for their neuropsychiatric symptoms. 1 However, arrhythmia may also contribute to neuropsychiatric symptoms in COVID-19 patients and should not be neglected.

Through a literature search, we summarized abnormal electrocardiographic findings in COVID-19 patients. Sinus tachycardia was the most common arrhythmia found in the patients, with frequencies of 16.9%−70.4% (Table 1) . Atrial fibrillation (AF) may be the secondary common arrhythmia. However, its occurrence rates vary greatly between different reports, ranging from 1.9% to 62.5% (Table 1) . Premature beat, ST-T segment and T wave changes, non-sustained ventricular tachycardia, QT-interval (QTc) prolongation, paroxysmal supraventricular tachycardia, atrioventricular block, bifascicular block, and left anterior hemi-block may also occur in the patients with frequencies higher than 10% (Table 1 ).

In many cases of sinus tachycardia, cognitive and behavioral factors, somatic hypervigilance associated with anxiety, depression, and behavioral amplification contributes to symptom chronicity. 3 And a previous study indicated that, for the patients with inappropriate sinus tachycardia, the most common comorbid conditions were depression (25.6%) and anxiety (24.6%). 4 Although no evidence of an association between symptoms of anxiety or severe depression and AF risk, a significant association of symptoms of mild to moderate depression with increased AF risk has been identified. 5 Moreover, anxiety and depression may be associated with worsened AF. 6 Thus, antiarrhythmic drugs, such as amiodarone and metoprolol may be used for COVID-19 patients with ventricular arrhythmia. 7 We should pay attention to the COVID-19 patients with psychiatric disorders before COVID-19, as the infection may exacerbate pre-existing mental symptoms. 8 The antiarrhythmic drugs should be applied to these patients, if they showed arrhythmia after the infection, since that arrhythmia may worsen the neuropsychiatric symptoms. [3] [4] [5] [6] Chloroquine and hydroxychloroquine have been widely used in COVID-19 treatments. However, there is compelling evidence that chloroquine and hydroxychloroquine induce significant QTc prolongation and potentially increase the risk of arrhythmia (such as Torsade de pointes) ( Table 2 ). 9 Actually, among COVID-19

patients, approximately 10% developed QTc prolongation to a degree that generally leads to withdrawal of the drug. 9 Although clinicians did not find evidence that occurrence of either depressive or anxiety disorder is associated with abnormalities in QTc, 10 increased anxiety scores were associated with prolonged QTc intervals. 11 Therefore, (hydroxy)chloroquine should not be used for COVID-19 patients with anxiety disorders to avoid severe QTc prolongation.

Neither psychiatric symptoms nor arrhythmia in COVID-19 patients undergoing steroid treatments has been well described in the literature. Corticosteroid-induced psychosis is a rare but welldocumented disorder when corticosteroid was applied at a high dose. 12 And a rare case study in lupus previously reported that high dose corticosteroid was associated with increased AF. 13 However, no such side effects have been reported at lower doses.

Indeed, low-dose corticosteroids have been shown in septic shock and prophylactic use for AF postcardiac surgery or ventilatorinduced. 14, 15 Although there is no direct evidence that corticosteroids can prevent arrhythmia, they are likely safe in low or moderate dosages and may have a role in preventing AF development in COVID-19. 15 Corticosteroids might be applied to 

Remitting neuropsychiatric symptoms in COVID-19 patients: viral cause or drug effect

The differential psychological distress of populations affected by the COVID-19 pandemic

Postural tachycardia syndrome: a heterogeneous and multifactorial disorder

Natural history and clinical outcomes of inappropriate sinus tachycardia

Symptoms of anxiety and depression and risk of atrial fibrillation−the HUNT study

The effect of anxiety and depression on symptoms attributed to atrial fibrillation

COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies

COVID-19 pandemic and mental health consequences: systematic review of the current evidence

QT prolongation, Torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review

Association between depression, anxiety, and antidepressant use with T-wave amplitude and QT-interval

Reference Arrhythmia in COVID-19 patients treated with (hydroxy)chloroquine Frequency

QTc > 500 ms 23.1% (58/251)

QTc > 500 ms 10

Cardiovascular risk factors in depression. The role of anxiety and anger

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5)

Recurrent atrial fibrillation after high-dose methylprednisolone therapy in a girl with lupusassociated hemophagocytic syndrome

Impact of low-dose hydrocortisone on the incidence of atrial fibrillation in patients with septic shock: a propensity score-inverse probability of treatment weighting cohort study

Atrial fibrillation in COVID-19: a review of possible mechanisms